Clinical trial
Effects of a GLP-1 Formula Drink on Gut Microbiota and Glycemic Control in Prediabetic Individuals
Opening soon · Not applicable · 1 countries · Registry ID NCT07089732
Opening soonNot applicableInterventional
What this study is about
A clinical human dietary intervention trial was conducted to investigate the effects of GLP-1 FORMUL liquid supplementation in individuals with prediabetes or obesity, with a focus on improvements in glycemic and lipid parameters, body composition, and gut microbiota profiles.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 70 Years
SexAll
Healthy volunteersAccepted
ConditionObesity, Prediabetes
Full registry criteria
Inclusion Criteria: * Adults aged 18 to 70 years. * Clinically diagnosed with prediabetes (fasting plasma glucose: 100-125 mg/dL or HbA1c: 5.7-6.4%) or with a body mass index (BMI) of 25-34.9 kg/m², male or female. * Have not participated in similar clinical studies within the past three months. * Able to comprehend the informed consent form, including the study procedures, potential risks, and benefits, and able to provide written informed consent. Exclusion Criteria: * Diagnosed with autoimmune diseases or cancer. * Diagnosed with gastrointestinal chronic diseases such as irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, celiac disease, bowel control disorders, fecal incontinence, pancreatitis, peptic ulcer disease, colorectal cancer, short bowel syndrome, ulcerative colitis, lactose intolerance, or chronic diarrhea. * History of gastrointestinal surgery. * Planning pregnancy in the near future (including male partners), currently pregnant, or breastfeeding women. * Known allergy or hypersensitivity to probiotics or any of the study product ingredients. * History of major psychiatric disorders. * History of substance abuse or alcohol dependency.
Treatments and study arms
GLP-1 formula liquid drink
Dietary Supplement
One glass jar (50 g) of the GLP-1 formula liquid drink was administered once daily, 30 minutes prior to the first meal of the day.
Placebo
Dietary Supplement
One glass jar (50 g) of the placebo liquid drink was administered once daily, 30 minutes prior to the first meal of the day.
Primary outcomes
Change from baseline in BMI at weeks 8 and 12Week 0, 8 and 12
Assessment of changes in BMI at baseline, week 8, and week 12
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Chung Shan Medical University🇹🇼 Taichung, South, Taiwan
Chin-Lin Hsu ProfessorContact